{
    "clinical_study": {
        "@rank": "100997", 
        "acronym": "BIRTH", 
        "arm_group": [
            {
                "arm_group_label": "TDM1 concommitant with RT", 
                "arm_group_type": "Experimental", 
                "description": "T-DM1 (First injection day 1) followed by brain sequential RT (start day D3), second injection T-DM1 day 22."
            }, 
            {
                "arm_group_label": "TDM1 during and after RT", 
                "arm_group_type": "Experimental", 
                "description": "Brain sequential RT (start day 1) followed by T-DM1 (First injection day 15), second injection T-DM1 day 36."
            }, 
            {
                "arm_group_label": "RT before TDM1", 
                "arm_group_type": "Experimental", 
                "description": "Brain sequential RT (start day 1) followed by T-DM1 (First injection day 22), second injection T-DM1 day 43."
            }, 
            {
                "arm_group_label": "TDM1 before RT", 
                "arm_group_type": "Experimental", 
                "description": "T-DM1 (First injection day 1) followed by brain sequential and concomitant RT (start day D18), second injection T-DM1 day 22."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the optimal sequences of combined trastuzumab\n      emtansine (T-DM1) and whole-brain radiotherapy in patients presenting brain metastases from\n      HER2-positive breast cancer in terms of acute toxicities and blood/cerebrospinal fluid T-DM1\n      pharmacokinetics."
        }, 
        "brief_title": "Patients With Brain Metastases From HER2-positive Breast Cancer", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "HER2-positive Breast Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Determine the best sequences."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed invasive breast cancer with stage IV disease.\n\n          2. HER-2 positive primary tumor, defined as: IHC3+, or IHC2+ and ISH positive.\n\n          3. Non operable brain metastases (n \u2265 2) with at least one measurable CNS lesion \u2265 10 mm\n             on T1-weighted gadolinium-enhanced MRI.\n\n          4. No stereotaxie radiotherapy indication\n\n          5. At least two weeks from any specific breast cancer treatment (such as Trastuzumab,\n             chemotherapy, immunotherapy/biological response modifiers, endocrine therapy and\n             radiotherapy).\n\n          6. Adequate hematologic function (ANC \u22651x109/L, platelets \u2265100 000/L; Hb >10g/dL), renal\n             function (creatinine \u2264 1.5x UNL) and hepatic function (albumin \u22652.5 g/dL; serum\n             bilirubin \u22641.5x ULN unless due to Gilbert's syndrome; AST and ALT \u2264 5x ULN if\n             documented liver metastasis or \u2264 3x ULN without liver metastasis).\n\n          7. At least 18 years old.\n\n          8. ECOG Performance Status of 0 to 2.\n\n          9. Life expectancy \u2265 3 months.\n\n         10. Potentially reproductive patients must agree to use an effective contraceptive method\n             while on treatment, beginning 2 weeks before the first dose of investigational\n             product and for 28 days after the final dose of investigational product for women.\n             Males able to father a child must practice adequate methods of birth control or\n             practice complete abstinence from intercourse from the first dose of investigational\n             treatment until one week after the final dose of investigational treatment.\n\n         11. Women of childbearing potential must have a negative serum pregnancy test within 14\n             days of enrollment and/or urine pregnancy test 48 hours prior to the administration\n             of the first study treatment.\n\n         12. Patients must be affiliated to a Social Security System.\n\n         13. Patient information and written informed consent form signed.\n\n        Exclusion Criteria:\n\n          1. Previous whole brain radiotherapy (WBRT) or brain stereotaxie radiotherapy.\n\n          2. Planned or concurrent systemic treatment or radiation therapy (other than\n             corticosteroid, bisphosphonates or mannitol).\n\n          3. Known contra-indication to MRI.\n\n          4. Active concurrent malignancy. If there is a history of prior malignancy, the patient\n             must be disease free for at least 10 years.\n\n          5. Patients with other concurrent severe and/or uncontrolled medical disease which could\n             compromise participation in the study, such as :\n\n               -  infection,\n\n               -  cardiac disease such as uncontrolled hypertension, congestive cardiac failure,\n                  ventricular arrhythmias, active ischemic heart disease, myocardial infarction\n                  within one year, LVEF \u2264 50%,\n\n               -  current active hepatic or renal disease\n\n          6. Pregnant women, women who are likely to become pregnant or are breast-feeding.\n\n          7. Patients with significantly altered mental status prohibiting the understanding of\n             the study or with psychological, familial, sociological or geographical condition\n             potentially hampering compliance with the study protocol and follow-up schedule;\n             those conditions should be discussed with the patient before registration in the\n             trial.\n\n          8. Known hypersensibility to any component of T-DM1\n\n          9. Patients who received any other investigational drugs within the 30 days prior to the\n             screening visit.\n\n         10. Individual deprived of liberty or placed under the authority of a tutor.\n\n         11. Leptomeningeal metastases diagnosed by MRI\n\n         12. Inclusion in another protocol within 30 days\n\n         13. Brain metastases with severe intracranial hypertension clinical signs\n\n         14. Other cancer except the known primary tumor or in situ cervix cancer or basocellular\n             carcinoma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02135159", 
            "org_study_id": "VA2012/38"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "TDM1 concommitant with RT", 
                    "TDM1 during and after RT", 
                    "RT before TDM1", 
                    "TDM1 before RT"
                ], 
                "description": "administration of the TDM1 by IV perfusion", 
                "intervention_name": "TDM1", 
                "intervention_type": "Drug", 
                "other_name": "no other names"
            }, 
            {
                "arm_group_label": [
                    "TDM1 concommitant with RT", 
                    "TDM1 during and after RT", 
                    "RT before TDM1", 
                    "TDM1 before RT"
                ], 
                "description": "local RT", 
                "intervention_name": "Brain Sequential RT", 
                "intervention_type": "Radiation", 
                "other_name": "No other names"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Montpellier", 
                    "country": "France", 
                    "zip": "34298"
                }, 
                "name": "Institut regional du Cancer - Val d Aurelle"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase I Study to Evaluate the Feasibility of Different Sequences of Combined Trastuzumab Emtansine (T-DM1) and Whole-brain Radiotherapy in Patients With Brain Metastases From HER2-positive Breast Cancer", 
        "overall_official": {
            "affiliation": "ICM", 
            "last_name": "David AZRIA", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the optimal sequences of combined trastuzumab emtansine (T-DM1) and whole-brain radiotherapy in patients presenting brain metastases from HER2-positive breast cancer in terms of acute toxicities and blood/cerebrospinal fluid T-DM1 pharmacokinetics.", 
            "measure": "optimal sequences of combined treatment", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02135159"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Objective responses (complete and partial response) by MRI according to the RECIST criteria (v1.1) and volumetric assessment", 
            "measure": "objective response", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "Centre Val d'Aurelle - Paul Lamarque", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Val d'Aurelle - Paul Lamarque", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}